Brookline analyst Kemp Dolliver upgraded Dare Bioscience to Buy from Hold with a $3 price target. The analyst cites the company’s improved funding for the upgrade.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
- DARE Earnings this Week: How Will it Perform?
- Biotech Alert: Searches spiking for these stocks today
- Dare Bioscience selected as spoke for ARPA-H Investor Catalyst Hub
- Daré Bioscience Secures Funding and Forges Royalty Agreements
